JFGIW
BCRX icon

Johnson Financial Group Inc (Wisconsin)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Johnson Financial Group Inc (Wisconsin)’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-369
Closed -$2.92K – 864
2024
Q4 		$2.92K Sell
369
-96
-21% -$729 ﹤0.01% 777
2024
Q3 		$3.53K Buy
+465
New +$3.54K ﹤0.01% 827

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Johnson Financial Group Inc (Wisconsin)'s BCRX Position: Q1 2025 in Review

Johnson Financial Group Inc (Wisconsin) sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2025, closing a stake of 369 shares — an estimated $2.92K sold.

Johnson Financial Group Inc (Wisconsin) first reported a position in BCRX in Q3 2024 and held it in 2 quarters. The position peaked at $3.53K in Q3 2024. 274 funds tracked by Wall St. Rank hold BCRX as of Q1 2025.

  • Johnson Financial Group Inc (Wisconsin) reported no remaining BioCryst Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Johnson Financial Group Inc (Wisconsin) sold 369 BioCryst Pharmaceuticals shares in Q1 2025, an estimated $2.92K.
  • Johnson Financial Group Inc (Wisconsin) first reported a position in BioCryst Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Johnson Financial Group Inc (Wisconsin)'s BioCryst Pharmaceuticals position peaked at $3.53K in Q3 2024.
  • 274 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2025.

Based on Johnson Financial Group Inc (Wisconsin)'s 13F filing for Q1 2025, filed 15 May 2025.